Adenosine A2A Receptor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The adenosine A2A receptor (A2AR) is a G protein-coupled receptor (GPCR) that plays a critical role in modulating dopaminergic signaling in the striatum and has emerged as a significant therapeutic target in Parkinson's Disease. Antagonists of the A2A receptor, such as istradefylline, have demonstrated efficacy in reducing "off" time in Parkinson's Disease patients. [1]
The adenosine A2A receptor is encoded by the ADORA2A gene and is predominantly expressed in the striatum, olfactory tubercle, and nucleus accumbens of the brain[2]. Within the basal ganglia, A2A receptors are highly enriched in striatopallidal "indirect pathway" neurons, where they [3]
modulate the activity of dopaminergic signaling in a manner opposite to D1 receptors. [4]
This receptor has attracted considerable attention in neurodegenerative disease research due to its: [5]
The A2A receptor is a Class A GPCR consisting of: [6]
The receptor binds adenosine as its endogenous ligand, with varying affinity depending on the receptor subtype. A2A receptors have higher affinity for adenosine compared to A2B receptors but lower affinity than A1 receptors.
Upon activation by adenosine, A2A receptors couple to Gs/olf proteins, leading to:
The Gs/olf coupling distinguishes A2A receptors from A1 receptors (Gi/o coupled) and creates a unique signaling profile in striatal neurons[1:1].
| Agent | Type | Status | Application |
|---|---|---|---|
| Istradefylline (Nouriast) | A2A antagonist | Approved (Japan, US) | Parkinson's Disease "off" time reduction |
| Preladenant | A2A antagonist | Clinical trials | Parkinson's Disease |
| Vipadenant | A2A antagonist | Clinical trials | Parkinson's Disease |
| KW-6002 (Istradefylline) | A2A antagonist | Approved | Parkinson's Disease |
| Caffeine | Non-selective antagonist | Over-the-counter | Research, mild stimulation |
In Parkinson's Disease, the loss of dopaminergic neurons in the substantia nigra pars compacta leads to:
The net effect is excessive inhibitory output from the basal ganglia, producing the cardinal motor symptoms of Parkinson's Disease: bradykinesia, rigidity, and tremor.
A2A and D2 receptors exhibit antagonistic interactions in striatopallidal neurons:
This crosstalk provides the therapeutic rationale for A2A antagonists in Parkinson's Disease[3:1].
A2A receptor antagonists provide several benefits in Parkinson's Disease:
Multiple preclinical studies have demonstrated neuroprotective properties of A2A receptor antagonists:
Several clinical trials have investigated the neuroprotective potential of A2A antagonists:
A2A receptor expression and function are altered in Parkinson's Disease:
| Condition | A2A Receptor Involvement |
|---|---|
| Huntington's Disease | Elevated A2A in striatum; antagonists may provide benefit |
| Alzheimer's Disease | Modulatory role in cognition; conflicting evidence |
| Multiple System Atrophy | Potential therapeutic target |
| Amyotrophic Lateral Sclerosis | Investigated for neuroprotection |
Genetic variations in the ADORA2A gene have been associated with:
A2A antagonists may interact with:
Current research areas include:
The study of Adenosine A2A Receptor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Schiffmann SN, Fisone G, Mones R, et al. Adenosine A2A receptors and basal ganglia physiology. 2007. ↩︎ ↩︎
Fredholm BB, IJzerman AP, Jacobson KA, et al. International Union of Basic and Clinical Pharmacology. 2001. ↩︎
Jenner P, Mori A, Hauser R, et al. Adenosine A2A receptor antagonists, movement disorders and Parkinson's Disease. 2009. ↩︎ ↩︎
Kase H, Kuriyama K, Ohno T, et al. Istradefylline (KW-6002): a novel selective adenosine A2A receptor antagonist for the treatment of Parkinson's Disease. 2006. ↩︎
Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets—what are the challenges? Nat Rev Drug Discov. 2013. ↩︎
Pinna A. Adenosine A2A receptor antagonists in Parkinson's Disease: progress in clinical trials from the newly approved istradefylline to presynaptic A2A receptors. 2019. ↩︎